First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Fulcrum Therapeutics, Inc.

    FULC · 5 developments mapped · last assessed 2026-09-02

    Market Ontology has mapped 5 macro, policy, and market developments to Fulcrum Therapeutics, Inc. since 2026-08-17. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for FULC yet, so no modelled value is shown. The FULC valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run FULC on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for FULC. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Open question

      Fulcrum Therapeutics, Inc. to Merge with Slate Medicines, Inc.

      Direct merger terms, equity dilution, cash dividend, strategic shift, and new pipeline integration.

      · Moves future growth rates (revenue, pipeline success), cost of capital (wacc due to perceived risk change), terminal value assumptions (long term competitive position)

    What changed, by assumption

    Future growth rates (revenue, pipeline success)
    • 2026-08-17Fulcrum Therapeutics, Inc. to Merge with Slate Medicines, Inc.
    Future growth rates (revenue, pipeline expansion)
    • 2026-08-17Fulcrum Therapeutics, Inc. to Acquire Slate Medicines, Inc.
    Future growth rate (if capital enables new projects)
    • 2026-08-17Fulcrum Therapeutics, Inc. Follow-On — $245M
    Future r&d spending capacity
    • 2026-08-17Slate Medicines, Inc. Follow-On — $245M
    Future growth rates (synergies, expanded pipeline)
    • 2026-09-02Fulcrum Therapeutics, Inc. Files S-4 Registration Statement for Merger

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-08-17Share countBullishThe merger involves issuing shares to Slate stockholders and investors in a concurrent investment, significantly increasing the total shares outstanding.1.00
    2026-08-17Valuation multipleBearishIncremental float typically compresses near-term multiple absent revenue acceleration.0.70
    2026-08-17Share countBullishPrimary equity issuance increases diluted share count.0.70
    2026-08-17Share countBullishStock component of consideration dilutes existing acquirer holders.0.70
    2026-08-17Net debtBullishCash component of consideration is typically debt-funded, raising net debt.0.70
    2026-08-17RevenueBullishAcquisition adds target revenue to acquirer P&L on close.0.70

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-02Fulcrum Therapeutics, Inc. Files S-4 Registration Statement for Mergermixed3-12m0.60
    2026-08-17Fulcrum Therapeutics, Inc. to Acquire Slate Medicines, Inc.mixed1-5y0.80
    2026-08-17Fulcrum Therapeutics, Inc. Follow-On — $245Mmixed1-3m0.80
    2026-08-17Fulcrum Therapeutics, Inc. to Merge with Slate Medicines, Inc.mixed1-3m0.90
    2026-08-17Slate Medicines, Inc. Follow-On — $245Mmixed1-3m0.70